A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Research Site
-
-
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Research Site
-
-
Massachusetts
-
Springfield, Massachusetts, Forenede Stater, 01199
- Research Site
-
-
Missouri
-
St. Louis, Missouri, Forenede Stater, 63110
- Research Site
-
-
New York
-
Buffalo, New York, Forenede Stater, 14215
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Research Site
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Research Site
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age ≥ 40 years at the time of screening
- Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
- Cohort 1 only: A primary diagnosis of clinically stable physician-diagnosed COPD upon entry into the study meeting one of the following criteria:
- Subjects who have experienced a severe AECOPD requiring inpatient hospitalization in the previous 12 months
- Subject who had one severe AECOPD requiring ED visits in the past 9 months
- Subjects who are currently on LTOT.
- Cohort 1 only: Stable COPD for 4 weeks prior to screening, as defined by no change in ICS therapy and no use of oral corticosteroids or antibiotics for a respiratory tract infection.
- Cohort 1 only: Forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 0.70 or lower limits of normal (LLN).
- Cohort 1 only: FEV1 < 60% predicted normal value.
- Cohort 2 only: A primary diagnosis of physician-diagnosed AECOPD requiring admission to the hospital.
- Current smoker or ex-smoker with a tobacco history of ≥ 10 pack-years (one pack year = 20 cigarettes smoked per day for 1 year).
- Ability and willingness to complete the appropriate follow-up period of time as required by the protocol.
- Able to read and write and use the electronic devices (English or Spanish version).
Exclusion Criteria:
- Participation (defined as administration of at least one dose of investigational product) in another clinical study, the last follow-up visit of which is within 12 weeks (for a small molecule drug) and (6 months for a large molecule drug) of entry into this study.
- Any condition that, in the opinion of the investigator would interfere with interpretation of subject safety or study results.
- Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
- The presence of another chronic pulmonary or systemic disease, which in the opinion of the investigator or medical monitor might affect the analysis of the data (eg, idiopathic pulmonary fibrosis, sarcoidosis, active cancer or autoimmune disease).
- History of immunodeficiency.
- Current alcohol or drug abuse or a history of unsuccessfully treated alcohol or drug abuse within the past year.
- Cohort 2 only: Diagnosis of an acute disease/condition (eg, congestive heart failure, acute myocardial infarction, pneumonia, or pulmonary embolus) that is the primary reason for the subject's hospitalization.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Cohort 2
Subjects who are recruited on admission to hospital for AECOPD.
|
|
Cohort 1
Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Identify biomarkers for evaluation of efficacy in subjects presenting with AECOPD
Tidsramme: 12 months
|
Investigate changes in physiological measures, symptoms, and blood, urine and sputum biomarkers in subjects with stable COPD during AECOPD, and as subjects return to clinical stability.
|
12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hospitalization, treatment and discharge of COPD subjects
Tidsramme: 12 months
|
Gain an understanding of the reasons subjects with COPD may be hospitalized for their AECOPD and to understand the criteria physicians use for treatment and discharge.
|
12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Joseph Parker, MD, MedImmune LLC
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MI-CP221
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .